437 related articles for article (PubMed ID: 34535088)
1. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
Zeng M; Yan X; Wu W
BMC Cardiovasc Disord; 2021 Sep; 21(1):446. PubMed ID: 34535088
[TBL] [Abstract][Full Text] [Related]
2. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
[TBL] [Abstract][Full Text] [Related]
3. Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation.
Kang IS; Shehata I; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
Heart Vessels; 2016 Sep; 31(9):1405-11. PubMed ID: 26337620
[TBL] [Abstract][Full Text] [Related]
4. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
[TBL] [Abstract][Full Text] [Related]
5. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
[TBL] [Abstract][Full Text] [Related]
6. Late Restenosis After Both First-Generation and Second-Generation Drug-Eluting Stent Implantations Occurs in Patients With Drug-Eluting Stent Restenosis.
Habara S; Kadota K; Kuwayama A; Shimada T; Ohya M; Miura K; Amano H; Kubo S; Hyodo Y; Otsuru S; Tada T; Tanaka H; Fuku Y; Goto T
Circ Cardiovasc Interv; 2016 Dec; 9(12):. PubMed ID: 27932532
[TBL] [Abstract][Full Text] [Related]
7. Comparison of in-stent neoatherosclerosis and tissue characteristics between early and late in-stent restenosis in second-generation drug-eluting stents: an optical coherence tomography study.
Sabbah M; Kadota K; El-Eraky A; Kamal HM; Abdellah AT; El Hawary A
Int J Cardiovasc Imaging; 2017 Oct; 33(10):1463-1472. PubMed ID: 28444549
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
[TBL] [Abstract][Full Text] [Related]
9. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
[TBL] [Abstract][Full Text] [Related]
10. Relationship between uric acid to albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.
Liu W; Ding K; Bao J; Hu Y; Gui Y; Ye L; Wang L
Coron Artery Dis; 2023 Dec; 34(8):589-594. PubMed ID: 37855441
[TBL] [Abstract][Full Text] [Related]
11. Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study.
Basavarajaiah S; Naganuma T; Latib A; Sticchi A; Ciconte G; Panoulas V; Chieffo A; Montorfano M; Carlino M; Colombo A
Catheter Cardiovasc Interv; 2016 Oct; 88(4):522-528. PubMed ID: 26715370
[TBL] [Abstract][Full Text] [Related]
12. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
14. Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study.
Rittger H; Wöhrle J; Brachmann J; Hohenforst-Schmidt W; Schlundt C; Lonke S; von Cranach M; Markovic S; Achenbach S; Waliszewski M
Catheter Cardiovasc Interv; 2016 Oct; 88(4):529-534. PubMed ID: 26893095
[TBL] [Abstract][Full Text] [Related]
15. Angiography and Optical Coherence Tomography Assessment of the Drug-Coated Balloon ESSENTIAL for the Treatment of In-Stent Restenosis.
de la Torre Hernández JM; Garcia Camarero T; Lozano Ruiz-Poveda F; Urbano-Carrillo CA; Sánchez Pérez I; Cano-García M; Saez R; Andrés Morist A; Molina E; Pinar E; Torres A; Lezcano EJ; Gutierrez H; Arnold RJ; Zueco J
Cardiovasc Revasc Med; 2020 Apr; 21(4):508-513. PubMed ID: 31401071
[TBL] [Abstract][Full Text] [Related]
16. Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis.
Nojima Y; Yasuoka Y; Kume K; Adachi H; Hattori S; Matsutera R; Kohama Y; Sasaki T
Coron Artery Dis; 2014 Dec; 25(8):638-44. PubMed ID: 25076360
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of myocardial SPECT to detect in-stent restenosis after drug-eluting stent implantation.
Park HE; Koo BK; Park KW; Paeng JC; Lee HY; Kang HJ; Kim HS
Int J Cardiovasc Imaging; 2012 Dec; 28(8):2125-34. PubMed ID: 22395666
[TBL] [Abstract][Full Text] [Related]
18. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
[TBL] [Abstract][Full Text] [Related]
19. Second-generation drug-eluting stents versus drug-coated balloons for the treatment of coronary in-stent restenosis: A systematic review and meta-analysis.
Kokkinidis DG; Prouse AF; Avner SJ; Lee JM; Waldo SW; Armstrong EJ
Catheter Cardiovasc Interv; 2018 Aug; 92(2):285-299. PubMed ID: 29024274
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of drug-coated balloon angioplasty in early versus late occurring drug-eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials.
Koch T; Cassese S; Xhepa E; Mayer K; Tölg R; Hoppmann P; Laugwitz KL; Byrne RA; Kastrati A; Kufner S
Catheter Cardiovasc Interv; 2020 Nov; 96(5):1008-1015. PubMed ID: 31789486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
